Nautilus Biotechnology IPO

Nautilus is a biotechnology company who is developing a proteomics platform enabling a dramatic acceleration of basic science research, significantly improving the success rate of therapeutic development, and enhancing opportunities for personalized and predictive medicine.

Register for Details

For more details on financing and valuation for Nautilus Biotechnology, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Updated on: Apr 18, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.